Kura Oncology (NASDAQ:KURA) was the target of unusually large options trading on Thursday. Stock investors bought 699 put options on the company. This represents an increase of 694% compared to the typical daily volume of 88 put options.
Institutional investors and hedge funds have recently modified their holdings of the business. MetLife Investment Advisors LLC bought a new stake in shares of Kura Oncology in the fourth quarter valued at $155,000. Barclays PLC raised its stake in shares of Kura Oncology by 67.0% in the first quarter. Barclays PLC now owns 8,977 shares of the company’s stock valued at $168,000 after buying an additional 3,600 shares during the period. American International Group Inc. raised its stake in shares of Kura Oncology by 42.0% in the fourth quarter. American International Group Inc. now owns 13,574 shares of the company’s stock valued at $208,000 after buying an additional 4,012 shares during the period. DekaBank Deutsche Girozentrale bought a new stake in shares of Kura Oncology in the first quarter valued at $226,000. Finally, Element Capital Management LLC bought a new stake in shares of Kura Oncology in the first quarter valued at $238,000. Hedge funds and other institutional investors own 70.24% of the company’s stock.
Get Kura Oncology alerts:Shares of KURA opened at $17.20 on Friday. The firm has a market capitalization of $583.69 million, a price-to-earnings ratio of -11.32 and a beta of 4.28. The company has a debt-to-equity ratio of 0.04, a quick ratio of 12.37 and a current ratio of 12.37. Kura Oncology has a 1 year low of $5.90 and a 1 year high of $24.02.
Kura Oncology (NASDAQ:KURA) last issued its earnings results on Tuesday, May 8th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.35) by ($0.11). research analysts anticipate that Kura Oncology will post -1.75 earnings per share for the current fiscal year.
A number of analysts recently commented on KURA shares. Zacks Investment Research upgraded Kura Oncology from a “hold” rating to a “buy” rating and set a $22.00 price target on the stock in a report on Wednesday, March 21st. Cann reiterated a “buy” rating and set a $27.00 price target on shares of Kura Oncology in a report on Tuesday, April 17th. BidaskClub lowered Kura Oncology from a “strong-buy” rating to a “buy” rating in a report on Friday, March 16th. ValuEngine upgraded Kura Oncology from a “sell” rating to a “hold” rating in a report on Monday, April 2nd. Finally, Citigroup set a $28.00 price target on Kura Oncology and gave the stock a “buy” rating in a report on Friday, February 16th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the company. Kura Oncology presently has an average rating of “Buy” and a consensus target price of $22.00.
Kura Oncology Company Profile
Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancers. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.
No comments:
Post a Comment